W. Lescaut

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

EGFR Antagonists in Cancer Treatment

Lung Cancer

Neocentromeres: Role in Human Disease, Evolution, and Centromere Study

Head and neck cancer

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

Targeting DNA topoisomerase II in cancer chemotherapy

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

Cardiotoxicity of Antitumor Drugs

Structural Dynamics of Eukaryotic Chromosome Evolution

Photopharmacology: Beyond Proof of Principle

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

Characterization of centromere alterations in liposarcomas

HER2 genetic polymorphism and pharmacodynamics of trastuzumab-based treatment in breast cancer patients